Streptamer versus tetramer-based selection of functional cytomegalovirus-specific T cells

Journal of the Formosan Medical Association

Volumn 112, Issue 6, 2013, Pages 338-345

  Wang, Xin Chao ^a,b,c   Pang, Hua ^b   Xu, Xun ^c,d   Schmitt, Anita ^e   Freund, Mathias ^c   Schmitt, Michael ^e   Chen, Bao An ^a  

^a AFFILIATED ZHONGDA HOSPITAL OF SOUTHEAST UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF ROSTOCK   (Germany)

^d INSTITUTE OF MATERIALS RESEARCH   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Adoptive immunotherapy; Cytomegalovirus; Cytomegalovirus specific T cells; Stem cell transplantation; Streptamers; Tetramer

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON; GRANZYME B; HLA A2 ANTIGEN; POLYMER; STREPTAMER; TETRAMER; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ARTICLE; BLOOD DONOR; CD8+ T LYMPHOCYTE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CRYOPRESERVATION; CYTOKINE RELEASE; CYTOMEGALOVIRUS; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; FUNCTIONAL STATUS; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LYMPHOCYTE PROLIFERATION; PERIPHERAL BLOOD MONONUCLEAR CELL;

ADOPTIVE TRANSFER; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; CYTOMEGALOVIRUS; GRANZYMES; HLA-A2 ANTIGEN; HUMANS; IMMUNOMAGNETIC SEPARATION; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION;

EID: 84879141223     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/j.jfma.2012.02.020     Document Type: Article

References (25)

1. Junghanss C., Boeckh M., Carter R.A., Sandmaier B.M., Maris M.B., Maloney D.G., et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002, 99:1978-1985.
2. Ljungman P., Brand R., Einsele H., Frassoni F., Niederwieser D., Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003, 102:4255-4260.
3. Boeckh M., Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009, 113:5711-5719.
4. Winston D.J., Young J.A., Pullarkat V., Papanicolaou G.A., Vij R., Vance E., et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008, 111:5403-5410.
5. Schmidt G.M., Horak D.A., Niland J.C., Duncan S.R., Forman S.J., Zaia J.A. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med 1991, 324:1005-1011.
6. Grigoleit G.U., Kapp M., Hebart H., Fick K., Beck R., Jahn G., et al. Dendritic cell vaccination in allogeneic stem cell recipients: induction of human cytomegalovirus (HCMV)-specific cytotoxic T lymphocyte responses even in patients receiving a transplant from an HCMV-seronegative donor. J Infect Dis 2007, 196:699-704.
7. Riddell S.R., Watanabe K.S., Goodrich J.M., Li C.R., Agha M.E., Greenberg P.D. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992, 257:238-241.
8. Einsele H., Roosnek E., Rufer N., Sinzger C., Riegler S., Löffler J., et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002, 99:3916-3922.
9. Cobbold M., Khan N., Pourgheysari B., Tauro S., McDonald D., Osman H., et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005, 202:379-386.
10. Neudorfer J., Schmidt B., Huster K.M., Anderl F., Schiemann M., Holzapfel G., et al. Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens. J Immunol Methods 2007, 320:119-131.
11. Yao J., Bechter C., Wiesneth M., Götz M., Germeroth L., Guillaume P., et al. Multimer staining of CMVpp65 specific T cells for diagnosis and therapeutic purpose: a comparative study. Clin Infect Dis 2008, 46:96-105.
12. Haerter G., Manfras B.J., de Jong-Hesse Y., Wilts H., Mertens T., Kern P., et al. Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis. Clin Infect Dis 2004, 39:e88-e94.
13. Schmitt M., Schmitt A., Reinhardt P., Thess B., Manfras B., Lindhofer H., et al. Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis invitro and invivo of EpCAM positive tumor cells by cytotoxic T lymphocytes. Int J Oncol 2004, 25:841-848.
14. Boeckh M., Nichols W.G., Papanicolaou G., Rubin R., Wingard J.R., Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003, 9:543-558.
15. Lowance D., Neumayer H.H., Legendre C.M., Squifflet J.P., Kovarik J., Brennan P.J., et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999, 340:1462-1470.
16. Prentice H.G., Gluckman E., Powles R.L., Ljungman P., Milpied N., Fernandez Rañada J.M., et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 1994, 343:749-753.
17. Boivin G., Goyette N., Rollag H., Jardine A.G., Pescovitz M.D., Asberg A., et al. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther 2009, 14:697-704.
18. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D., et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995, 333:1038-1044.
19. Brestrich G., Zwinger S., Fischer A., Schmück M., Röhmhild A., Hammer M.H., et al. Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy. Am J Transplant 2009, 9:1679-1684.
20. Gillespie G.M., Wills M.R., Appay V., O'Callaghan C., Murphy M., Smith N., et al. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J Virol 2000, 74:8140-8150.
21. Knabel M., Franz T.J., Schiemann M., Wulf A., Villmow B., Schmidt B., et al. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat Med 2002, 8:631-637.
22. Rufer N., Zippelius A., Batard P., Pittet M.J., Kurth I., Corthesy P., et al. Exvivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood 2003, 102:1779-1787.
23. Whelan J.A., Dunbar P.R., Price D.A., Purbhoo M.A., Lechner F., Ogg G.S., et al. Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent. J Immunol 1999, 163:4342-4348.
24. Maile R., Wang B., Schooler W., Meyer A., Collins E.J., Frelinger J.A. Antigen-specific modulation of an immune response by invivo administration of soluble MHC class I tetramers. J Immunol 2001, 167:3708-3714.
25. Schmitt A., Tonn T., Busch D.H., Grigoleit G., Einsele H., Odendahl M., et al. Adoptive transfer and selective reconstitution of streptamer-selected CMV-specific CD8+ T cells leads to virus clearance in patients after allo-PBSCT. Transfusion 2011, 51:591-599.